Sponsor pipeline

GBG Forschungs GmbH clinical trial pipeline

5 active trials 4 recruiting 1 Phase 3 3 disease areas 3 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-02

What changed in the last 30 days

2026-09-12

NCT05306041 Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA… · Phase 2

2026-09-16

NCT05739591 Long-term Safety and Efficacy of GBG Study Participants

Phase 2		3
Phase 3		1

Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

NCT ID	Title	Condition	Status	Updated
Phase 3
NCT04595565	Sacituzumab Govitecan in Primary HER2-negative Breast Cancer	HER2-negative Breast Cancer	Active, Not Recruiting	2026-04-22
Phase 2
NCT05306041	Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA…	HER2-positive Breast Cancer	Recruiting	2026-09-11
NCT06201234	Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in…	Hormone Receptor Positive HER-2 Negative Breast Cancer	Recruiting	2025-12-01
NCT06607757	Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer	CCCA Assessed by Ki67 Drop Below <2.7% From Baseline	Recruiting	2025-04-02
Not specified
NCT05739591	Long-term Safety and Efficacy of GBG Study Participants	Breast Cancer	Recruiting	2026-09-15

Get alerts when GBG Forschungs GmbH's trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.